Urapidil is a mixed central 5HT1A receptor stimulant and a peripheral α-adrenergic antagonist. Urapidil is used in Europe, but it is not yet approved for use in the United States as of July 2006. It has desirable pharmacokinetics, rapidly and well absorbed and with a plasma half-life of approximately 3 hours.